A study in rats with Achilles tendon transection found that BPC-157 treatment greatly improved tendon healing, with increased collagen organization and improved tensile strength compared to controls
Key structural features include N14E and V17R substitutions (helix stabilisation), 25P/28P/29P proline substitutions (suppression of beta-sheet propensity and amyloid fibril formation, the primary instability mode of native human amylin), a C-terminal proline-to-tyrosine substitution (P37Y) for calcitonin-receptor activity, and N-terminal C20 fatty-diacid acylation via a gamma-Glu linker
Notably, the 1,4-dihydropyridine ring oxidized analogue (KL7) completely lost the adjuvant activity, presumably due to altered electronic structure, reduced conformational flexibility, or lost hydrogen bonding capacity (Extended Data Fig
"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial." The Lancet , 402(10404), 529-544